TET2 variants often represent an early event in the development of human myeloid malignancies, including AML, MDS, MPNs, and chronic myelomonocytic leukemia (CMML), as well as B- and T-cell neoplasms (Quivoron et al., 2011). Here, TET2 is linked to chronic myelomonocytic leukemia.